C-MER Eye Care Holdings Limited (HK:3309)
:3309
Want to see HK:3309 full AI Analyst Report?
Top Page
C-MER Eye Care Holdings Limited
(3309)
Select Model
Select Model
Rating:64Neutral
Price Target:
HK$1.50
▼(-11.76% Downside)
Action:ReiteratedDate:04/21/26
The score is supported primarily by strong cash flow and a stable, moderately levered balance sheet, but is held back by weak technicals (broad downtrend and negative momentum) and only average valuation support (mid-range P/E and modest dividend yield).
Positive Factors
Consistent positive operating cash flow
Sustained positive operating and free cash flow over multiple years provides durable internal funding for clinic maintenance, equipment refreshes and selective network expansion, reducing reliance on external capital and supporting resilience across medical service cycles.
Negative Factors
Earnings volatility and intermittent losses
Repeated swings between profit and loss reduce predictability of free cash flow and complicate long-term planning. For a healthcare services operator, this can hinder capacity investments, staff retention and consistent reinvestment in clinical capabilities.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent positive operating cash flow
Sustained positive operating and free cash flow over multiple years provides durable internal funding for clinic maintenance, equipment refreshes and selective network expansion, reducing reliance on external capital and supporting resilience across medical service cycles.
Read all positive factors
C-MER Eye Care Holdings Limited (3309) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.57B
Dividend Yield1.2%
Average Volume (3M)495.46K
Price to Earnings (P/E)20.7
Beta (1Y)1.08
Revenue Growth1.75%
EPS GrowthN/A
CountryHK
Employees2,041
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.04
Shares Outstanding1,232,342,900
10 Day Avg. Volume419,185
30 Day Avg. Volume495,465
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)1.17
Price to Sales (P/S)1.07
P/FCF Ratio9.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
C-MER Eye Care Holdings Limited Business Overview & Revenue Model
Company Description
C-MER Eye Care Holdings Ltd. engages in the provision of treatments and therapy services for ophthalmic diseases. It operates through the Provision of Ophthalmic Services and the Sale of Vision Aid Products segments. The company was founded by Shu...
How the Company Makes Money
C-MER primarily generates revenue by providing ophthalmic medical services to patients on a fee-for-service basis. Its key revenue streams typically include (1) outpatient services such as specialist consultations, eye examinations, and diagnostic...
C-MER Eye Care Holdings Limited Financial Statement Overview
Summary
Income Statement
73
Positive
Balance Sheet
78
Positive
Cash Flow
84
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.95B | 1.91B | 1.92B | 1.73B | 1.11B |
| Gross Profit | 548.66M | 527.62M | 618.96M | 365.34M | 309.44M |
| EBITDA | 327.66M | 209.18M | 363.38M | 194.31M | 177.80M |
| Net Income | 100.37M | -135.16M | 62.00M | -21.88M | 21.86M |
Balance Sheet | |||||
| Total Assets | 2.73B | 2.72B | 2.75B | 2.90B | 1.96B |
| Cash, Cash Equivalents and Short-Term Investments | 465.96M | 467.25M | 557.42M | 698.51M | 442.36M |
| Total Debt | 426.78M | 437.79M | 362.99M | 452.49M | 471.69M |
| Total Liabilities | 796.01M | 830.24M | 755.35M | 903.45M | 618.63M |
| Stockholders Equity | 1.77B | 1.75B | 1.85B | 1.87B | 1.33B |
Cash Flow | |||||
| Free Cash Flow | 223.94M | 124.50M | 245.30M | 100.63M | 19.18M |
| Operating Cash Flow | 301.47M | 283.12M | 361.15M | 191.86M | 148.41M |
| Investing Cash Flow | -169.66M | -174.72M | -245.37M | -210.65M | -392.72M |
| Financing Cash Flow | -212.38M | -194.92M | -242.88M | 293.68M | 85.12M |
C-MER Eye Care Holdings Limited Technical Analysis
Negative
1.70
Price Trends
1.39
Negative
1.53
Negative
1.71
Negative
Market Momentum
-0.03
Negative
40.79
Neutral
29.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3309, the sentiment is Negative. The current price of 1.7 is above the 20-day moving average (MA) of 1.29, above the 50-day MA of 1.39, and below the 200-day MA of 1.71, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 40.79 is Neutral, neither overbought nor oversold. The STOCH value of 29.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3309.
C-MER Eye Care Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
HK:3309
C-MER Eye Care Holdings Limited
1.26
-0.37
-22.70%
HK:1846
EuroEyes International Eye Clinic Limited
2.67
-0.07
-2.55%
HK:2219
Chaoju Eye Care Holdings Ltd.
2.86
0.40
16.26%
C-MER Eye Care Holdings Limited Corporate Events
C-MER Medical Sets 2026 AGM With Dividend Proposals and Share Buy-Back Mandate
Apr 17, 2026
C-MER Medical Holdings Limited has called its annual general meeting for 20 May 2026 in Central, Hong Kong, where shareholders will review the audited financial statements for the year ended 31 December 2025 and the reports of the board and audito...
C-MER Medical Announces Special Cash Dividend for 2025
Mar 27, 2026
C-MER Medical Holdings Limited has declared a special cash dividend of HKD 0.01 per share for the financial year ended 31 December 2025, reflecting the company’s decision to return additional capital to shareholders. The move signals managem...
C-MER Medical Swings Back to Profit on Higher Margins and Lower Impairments
Mar 27, 2026
C-MER Medical Holdings Limited reported a modest 1.8% rise in revenue to HK$1.95 billion for 2025 but delivered a strong turnaround in profitability, swinging from a loss of HK$108.3 million in 2024 to a profit of HK$111.2 million. Gross profit cl...
C-MER Medical Declares HKD 0.02 Final Dividend for FY2025
Mar 27, 2026
C-MER Medical Holdings Limited has declared a final ordinary cash dividend of HKD 0.02 per share for the financial year ended 31 December 2025, subject to shareholder approval at a meeting scheduled for 20 May 2026. The dividend will be paid in Ho...
C-MER Medical Signals Profit Turnaround on Network Optimisation, Absence of Impairment Charges
Mar 6, 2026
C-MER Medical Holdings Limited has issued a positive profit alert, indicating it expects to swing to a net profit of between HK$90 million and HK$110 million attributable to shareholders for the year ended 31 December 2025, compared with a HK$135....
C-MER Medical Sets March 2026 Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 6, 2026
C-MER Medical Holdings Limited has scheduled a board meeting for 27 March 2026 to review and approve the company’s audited annual results for the year ended 31 December 2025. The board will also consider whether to recommend a final dividend...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.